DDInter659 DDInter899
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Eptifibatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valdecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Collagenase clostridium histolyticum
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum
Eptifibatide may lead to a major life threatening interaction when taken with Anagrelide
Eptifibatide may lead to a major life threatening interaction when taken with Abciximab